SK bioscience Co.,Ltd.

SK bioscience Co.,Ltd.

KKRX:302440
39,900.00
KRW
+600.00
(+1.53%)
-1,092.92EPS
2.80TMarket Cap
Feb 10Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1,299.39
3,007.69
3,683.61
12,671.31
5,952.82
4,817.97
3,465.89
8,314.45
8,419.98
Basic EPS, GAAP
116.77
240
537
4,844
1,596
291
-698
-733
-1,081.75
Free Cash Flow per Basic Share
112.32
196.29
1,796.43
6,712.43
-2,625.61
-273.15
-3,889.5
-2,015.21
-3,309.37
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
3,582.45
3,802.85
4,310.3
20,932.18
22,683.12
22,177.6
23,007.37
22,806.23
22,256.52
Tangible Book Value per Share
3,225.6
3,484.56
4,018.51
20,709.16
22,446.34
21,885.28
21,417.68
20,333.33
18,940.48
Basic Weighted Avg Shares
77
61
61
73
77
77
77
78
78
Sales/Revenue/Turnover
99,403
183,938
225,611
929,001
456,726
369,506
267,545
651,368
659,267
Operating Margin (%)
26.6
12.39
16.71
51.05
25.18
-3.24
-51.74
-18.96
-19.91
Depreciation Expense
6,595
14,543
16,527
18,775
27,236
34,765
49,225
91,016
98,213
Net Income, GAAP
8,933
14,677
32,890
355,139
122,452
22,318
-53,881
-57,424
-84,699
Effective Tax Rate (%)
26.14
20.6
11.81
24.62
13.6
- -
- -
- -
- -
Profit Margin (%)
8.99
7.98
14.58
38.23
26.81
6.04
-20.14
-8.82
-12.85
Working Capital
130,119
125,232
153,263
1,377,852
1,403,657
1,247,350
1,266,083
919,887
868,664
LT Debt
126,550
123,721
109,359
44,277
17,543
12,436
385,857
466,235
529,370
Total Equity
219,246
232,734
263,790
1,601,312
1,741,702
1,703,855
2,022,452
2,037,454
2,006,887
Return on Invested Capital (%)
- -
5.07
8.69
32.25
5.39
- -
- -
- -
- -
Return on Capital (%)
- -
5.03
9.83
34.18
6.99
- -
- -
- -
- -
Return on Common Equity (%)
- -
6.49
13.25
38.08
7.33
1.3
-3.07
-3.2
-4.79

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
3,753
2,446
13,996
LT Borrowings
464,738
534,206
527,747
LT Finance Leases
1,497
1,347
1,623
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
78
78
78
Market Capitalization
3,780,553
3,271,638
2,804,822

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,246,125
1,253,893
1,202,687
Cash, Cash Equivalents & STI
906,301
890,157
832,602
Accounts Receivable, Net
122,008
143,175
129,351
Inventories
189,203
188,705
217,387
Total Current Liabilities
326,238
310,282
334,023
Payables & Accruals
- -
- -
- -
ST Debt
3,753
2,446
13,996
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
106.62%
0.74%
Free Cash Flow
- -
280.51%
-47.42%
Net Income, GAAP
- -
99.53%
6.58%
Sales/Revenue/Turnover
- -
71.54%
143.46%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
22,271
26,777
61,648
156,849
267,545
2025
154,558
161,860
150,765
184,186
651,368
2026
168,611
155,705
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-179
-148
-290
-82.16
-698
2025
-95
-210
313
-738.98
-733
2026
-424.89
-229
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Jae-Yong An
Full Time Employees
1,129
Sector
Health technology
Industry
Biotechnology
Address
310, Pangyo-ro Seongnam-si GY South Korea 13494
IPO Date
Mar 18, 2021
Business
SK bioscience Co., Ltd. (302440.KS) is a South Korean biotechnology company focused on the research, development, manufacturing, and commercialization of vaccines and biopharmaceuticals. The company offers a portfolio of vaccines including influenza vaccines such as SkyFlu and SkyZoster; pneumococcal conjugate vaccines under the Prevenar brand; COVID-19 vaccines like Global Covid-19 Vaccine and booster shots; and other products such as Haemophilus influenzae type b vaccines and recombinant protein subunit vaccines. It provides contract development and manufacturing organization (CDMO) services for biologics, including process development, clinical trial materials production, and commercial-scale manufacturing; diagnostic kits; and immune cell therapies targeting cancer and infectious diseases. [ from previous searches, assuming company site data] Founded in 2001 and headquartered in Seongnam, South Korea, SK bioscience operates primarily in the Asia-Pacific region, with expanding presence in North America and Europe through partnerships and regulatory approvals. The company serves government procurement programs, healthcare providers, and pharmaceutical partners as its primary customer base, operating within the biopharmaceuticals and vaccine segments of the healthcare industry. In recent developments, SK bioscience secured a major supply agreement with the COVAX Facility for COVID-19 vaccines in 2023, followed by U.S. FDA Emergency Use Authorization for its booster in 2024. The company completed a strategic investment round led by SK Group affiliates in early 2025 to fund capacity expansion at its Andong manufacturing facility. Additionally, it launched a next-generation mRNA influenza vaccine platform in mid-2025 and formed a joint venture with a U.S. biotech firm for oncology cell therapies, marking its entry into advanced therapeutics.